New Myths and Truths About Thyroid Cancer Education Initiative Aims to Shine a Light on the Truths about Thyroid Cancer
WOODCLIFF LAKE, NJ, September 15, 2015 – The Light of Life Foundation, ThyCa: Thyroid Cancer Survivors’ Association, Inc., and Eisai Inc. today announced the launch of Myths and Truths About Thyroid Cancer, an interactive, educational campaign designed to help dispel the myth that thyroid cancer is a “good cancer.” Because most thyroid cancers can be successfully treated, many are told if you are going to get cancer, thyroid cancer is the one to have, which has led to this misperception. However, whether successfully treated or not, the truth is all cancers can have a significant impact on a person’s life, beginning with the shock and distress of hearing the word “cancer” at diagnosis. In honor of Thyroid Cancer Awareness Month and the tens of thousands who receive a thyroid cancer diagnosis each year, Myths and Truths About Thyroid Cancer illustrates the life-changing realities of this disease.
Eiasi is pleased to announce that LENVIMATM (lenvatinib) is now approved for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC)
The incidence of thyroid cancer has steadily increased globally over the last 50 years, and as the most common endocrine malignancy, there remains a need for additional treatment options, particularly for patients with DTC whose cancer no longer responds to radioactive iodine (RAI) therapy. The most common types of thyroid cancer, papillary and follicular, are classified as differentiated thyroid cancer (DTC) and account for approximately 90 percent of all cases.
View all news...